Amber Sapp, NP
Family · Albany, GANPI 1568715340
Payments from drug & device makers
Across 293 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$779
- GSK$764
- AstraZeneca$726
- Regeneron Healthcare Solutions, Inc.$446
- Insmed, Inc.$417
- United Therapeutics Corporation$380
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,63797%
- Education$1993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 39 | $779 |
| GSK | 49 | $764 |
| AstraZeneca(2 entities) | 40 | $726 |
| Regeneron Healthcare Solutions, Inc. | 19 | $446 |
| Insmed, Inc. | 23 | $417 |
| United Therapeutics Corporation | 16 | $380 |
| Sanofi | 9 | $285 |
| Johnson & Johnson | 13 | $243 |
| Merck | 9 | $209 |
| Mallinckrodt Hospital Products Inc. | 4 | $194 |
| Bayer | 10 | $185 |
| Amgen | 7 | $166 |
| Grifols USA, LLC | 6 | $144 |
| Verona Pharma, Inc. | 4 | $113 |
| Electromed, Inc. | 7 | $107 |
| Actelion Pharmaceuticals US, Inc. | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Harmony Biosciences LLC | 4 | $69 |
| Pfizer | 4 | $66 |
| Baxter Healthcare | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 7 | $52 |
| Philips North America LLC | 2 | $48 |
| Mylan Specialty L.p. | 2 | $46 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $22 |
| CSL Behring | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $12 |
How this compares
$5,836 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 494 | $370,002 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 152 | $100,488 |
| Humira(Cf)Adalimumab | 13 | $88,551 |
| Dupixent SyringeDupilumab | 15 | $57,048 |
| Breo ElliptaFluticasone/Vilanterol | 95 | $56,735 |
| SymbicortBudesonide/Formoterol Fumarate | 178 | $53,594 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $41,822 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $21,957 |
| XareltoRivaroxaban | 23 | $17,345 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 638 | $16,474 |
| EliquisApixaban | 22 | $13,011 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,251 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $10,089 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 48 | $9,369 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $7,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $764 | $468,559674 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $726 | $154,082330 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $779 | $43,29769 claims |
| Johnson & JohnsonXarelto | $243 | $17,34523 claims |
| PfizerEliquis | $66 | $13,01122 claims |
| MerckDulera | $209 | $6,23518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Albany
- Jennifer BerryAlbany$16K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.